SEZanne: A phase 2 randomized, open-label, multicenter study to evaluate the optimal dose, safety, and efficacy of ABBV-706 in combination with atezolizumab (atezo) versus standard of care (SOC) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC).
Randomized trial evaluates safety and efficacy of ABBV-706 combined with atezolizumab for extensive-stage small cell lung cancer, suggesting a new treatment approach.
Key Points
The study aims to evaluate the safety, efficacy, and optimal dosing of ABBV-706 in combination with atezolizumab for previously untreated extensive-stage small cell lung cancer.
Randomized open-label phase 2 study across ~75 sites with up to 180 participants.
Participants aged ≥18 years with extensive-stage small cell lung cancer receiving first-line therapy.
Study consists of a safety lead-in with ~30 participants followed by a dose optimization stage with ~150 participants.
ABBV-706 plus atezolizumab aims to improve progression-free survival compared to standard-of-care treatment.
The study is ongoing and not yet completed, hence detailed results will be available upon completion.